Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
1999
Oral Administration of MIBG: Bioavailability and Toxicity
publication
Evidence: moderate
Author Information
Author(s): Kuin A, Rutgers M, Valk M A van der, Beijnen J H, Smets L A
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Can oral administration of MIBG be feasible and safe for patients?
Conclusion
Oral MIBG administration showed sufficient bioavailability and no gastrointestinal toxicity, making it suitable for further clinical investigation.
Supporting Evidence
- Orally administered MIBG demonstrated a bioavailability of 59%.
- The maximal tolerated dose of MIBG was found to be 60 mg kg−1.
- Only toxicity observed was a decrease in renal function.
- Repeated MIBG administration did not affect renal clearance.
Takeaway
This study looked at giving a medicine called MIBG by mouth instead of through a needle, and it found that it works well without hurting the stomach.
Methodology
The study investigated the bioavailability and toxicity of orally administered MIBG in an animal model.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website